Spitzer/IRS Imaging and Spectroscopy of the luminous infrared galaxy NGC 6052 (Mrk 297)

We present photometric and spectroscopic data of the interacting starburst galaxy NGC 6052 obtained with the Spitzer Space Telescope. The mid-infrared (MIR) spectra of the three brightest spatially resolved regions in the galaxy are remarkably similar and are consistent with dust emission from young nearly coeval stellar populations. Analysis of the brightest infrared region of the system, which contributes ~18.5 % of the total 16\micron flux, indicates that unlike similar off-nuclear infrared-bright regions found in Arp 299 or NGC 4038/9, its MIR spectrum is inconsistent with an enshrouded hot dust (T > 300K) component. Instead, the three brightest MIR regions all display dust continua of temperatures less than ~ 200K. These low dust temperatures indicate the dust is likely in the form of a patchy screen of relatively cold material situated along the line of sight. We also find that emission from polycyclic aromatic hydrocarbons (PAHs) and the forbidden atomic lines is very similar for each region. We conclude that the ionization regions are self-similar and come from young (about 6 Myr) stellar populations. A fourth region, for which we have no MIR spectra, exhibits MIR emission similar to tidal tail features in other interacting galaxies.Comment: 20 pages in preprint form, estimated 7 pages in ApJ Aeptember 10, 2007, v666n 2 issue, six encapsulated postscript figure

AGAPE, an experiment to detect MACHO's in the direction of the Andromeda galaxy

The status of the Agape experiment to detect Machos in the direction of the andromeda galaxy is presented.Comment: 4 pages, 1 figure in a separate compressed, tarred, uuencoded uufile. In case ofproblem contact [email protected]

AgapeZ1: a Large Amplification Microlensing Event or an Odd Variable Star Towards the Inner Bulge of M31

AgapeZ1 is the brightest and the shortest duration microlensing candidate event found in the Agape data. It occured only 42" from the center of M31. Our photometry shows that the half intensity duration of the event6 is 4.8 days and at maximum brightness we measure a stellar magnitude of R=18.0 with B-R=0.80 mag color. A search on HST archives produced a single resolved star within the projected event position error box. Its magnitude is R=22.Comment: 4 pages with 5 figure

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

S9788 is a new triazineaminopiperidine derivate capable of reversing multidrug resistance (MDR) in cells resistant to chemotherapeutic agents such as doxorubicin. It does not belong to a known class of MDR revertants, but its action involves the binding of P-glycoprotein. Thirty-eight evaluable patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone (16 patients) followed after disease progression with combination treatment of doxorubicin plus S9788 (12 patients) or upfront with the combination of doxorubicin plus S9788 (22 patients). S9788 was given i.v. as a loading dose of 56 mg m-2 over 30 min followed by doxorubicin given at 50 mg m-2 as a bolus infusion. Thereafter, a 2-h infusion of S9788 was administered at escalating doses ranging from 24 to 120 mg m-2 in subsequent cohorts of 4-10 patients. Pharmacokinetic analysis demonstrated that concentrations of S9788 that are known to reverse MDR in vitro were achieved in patients at non-toxic doses. Compared with treatment with doxorubicin alone, treatment with the combination of doxorubicin and S9788 produced a significant increase in the occurrence of WHO grade 3-4 granulocytopenia. Treatment with S9788 was cardiotoxic as it caused a dose-dependent and reversible increase in corrected QT intervals as well as clinically non-significant arrhythmias on 24- or 48-h Holter recordings. Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of S9788 may increase the risk of severe cardiac arrhythmias. Twenty-nine patients treated with S9788 plus doxorubicin were evaluable for response, and one patient, who progressed after treatment with doxorubicin alone, achieved a partial response. We conclude that S9788 administered at the doses and schedule used in this study results in relevant plasma concentrations in humans and can safely be administered in combination with doxorubicin

AGAPE: a microlensing search in the direction of M31

A status report of the microlensing search by the pixel method in the direction of M31, on the 2 meter telescope at Pic du Midi is given. Pixels are stable to a level better than 0.5%. Pixel variations as small as 0.02 magnitude can clearly be detected

Variable stars towards the bulge of M31: the AGAPE catalogue

We present the AGAPE astrometric and photometric catalogue of 1579 variable stars in a 14'x10' field centred on M31. This work is the first survey devoted to variable stars in the bulge of M31. The R magnitudes of the objects and the B-R colours suggest that our sample is dominated by red long-period variable stars (LPV), with a possible overlap with Cepheid-like type II stars. Twelve nova candidates are identified. Correlations with other catalogues suggest that 2 novae could be recurrent novae and provide possible optical counterparts for 2 supersoft X-ray sources candidates observed with Chandra.Comment: 11 pages, Latex, accepted for publication in A&

Transketolase catalysed upgrading of l-arabinose: the one-step stereoselective synthesis of l-gluco-heptulose

Conversion of biomass using biocatalysis is likely to become a technology that contributes significantly to the future production of chemical building blocks, materials and transport fuels. Here the synthesis of a value-added chemical from L-arabinose, a major component of the carbohydrates in sugar beet pulp (SBP), in a concise and sustainable manner has been investigated. Biocatalytic conversions using transketolase variants have been developed for the efficient, scalable synthesis of a rare naturally occurring ketoheptose, L-gluco-heptulose, from L-arabinose. New active E. coli TK mutants that readily accept L-arabinose were identified using a versatile colorimetric screening assay and the reaction was performed on a preparative scale

Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor

Contains fulltext : 69595.pdf (publisher's version ) (Closed access)PURPOSE: In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated. METHODS: Three intravenous cisplatin-regimens, given concurrently with radiation, were studied: daily low-dose (6 mg/m(2)) cisplatin, weekly 40 mg/m(2), three-weekly 100 mg/m(2). A (32)P-postlabeling technique was used to quantify adducts in normal tissue [white blood cells (WBC) and buccal cells] and tumor. RESULTS: Normal tissue samples for adduct determination were obtained from 63 patients and tumor biopsies from 23 of these patients. Linear relationships and high correlations were observed between the levels of two guanosine- and adenosine-guanosine-adducts in normal and tumor tissue. Adduct levels in tumors were two to five times higher than those in WBC (P<0.001). No significant correlations were found between adduct levels in normal tissues and primary tumor biopsies, nor between WBC and buccal cells. CONCLUSIONS: In concurrent chemoradiotherapy schedules, cisplatin adduct levels in tumors were significantly higher than in normal tissues (WBC). No evidence of a correlation was found between adduct levels in normal tissues and primary tumor biopsies. This lack of correlation may, to some extent, explain the inconsistencies in the literature regarding whether or not cisplatin-DNA adducts can be used as a predictive test in anticancer platinum therapy